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COVID-19 Antibody Testing as 
a Precondition for Employment: 
Ethical and Legal Considerations
Sara Gerke, Gali Katznelson, Dorit Reiss, and Carmel Shachar
Until there is a vaccine for SARS-CoV-2, we will have to negotiate between the interests of pandemic control through social distanc-
ing and the need for people to return to work and 
travel. Serological (antibody) testing may help bridge 
that gap by allowing us to identify who is no longer 
at risk for contracting and transmitting SARS-CoV-2 
and letting them resume normal activities, including 
employment. 
Several governments, including the United States, 
Germany, and the United Kingdom, have suggested 
that the presence of IgM and/or IgG antibodies to 
SARS-CoV-2 may be used to issue “immunity pass-
ports” or “certificates.”1 The U.S. Food and Drug 
Administration (FDA) has already allowed numer-
ous companies to sell antibody tests, and some work-
places have used them, including a law fi rm in Arizona 
and fi refi ghters in Illinois.2 At the time of writing, the 
World Health Organization’s stance is that there is not 
suffi  cient evidence on antibody-mediated immunity 
to ensure the accuracy of immunity passports.3 There 
may come a time, however, when we know more about 
COVID-19 immunity and have developed a test that is 
reliable and accurate enough to warrant further con-
sideration and implementation for broad antibody 
testing. Mass antibody testing, coupled with PCR test-
ing for SARS-CoV-2, could play a crucial role in restor-
ing our freedom of movement.4
In this article, we explore the ethical and legal con-
cerns of tying antibody testing to access to employ-
ment. We consider the ethical permissibility of both 
government required antibody testing programs and 
private programs initiated by employers in a variety 
of industries. We also articulate considerations that 
must be addressed in order for this testing program to 
be ethically implemented, such as privacy and equity. 
Lastly, we consider whether federal or state govern-
Sara Gerke, Dipl.-Jur. Univ., M.A.,  is the research fellow, medicine, artifi cial intelligence, and law at the Petrie-Flom Center 
for Health Law Policy, Biotechnology, and Bioethics, Harvard University, Cambridge, MA, USA. Ms. Gerke holds adegree in law 
(Dipl.-Jur. Univ.) from the University of Augsburg, Germany, and a Master’s degree in Medical Ethics and Law from King’s 
College London. Gali Katznelson, M.B.E., is a medical student at the Schulich School of Medicine & Dentistry, Western Uni-
versity, London, Ontario, Canada. She holds a Masters in Bioethics from Harvard Medical School. Dorit Reiss, Ph.D., L.L.B.,
is a Professor of Law and the James Edgar Hervey ’50 Chair of Litigation at the University of California Hastings College of 
Law, San Francisco, CA, USA. She holds a degree in Law and Political Science from the Faculty of Law in the Hebrew University 
of Jerusalem and a Ph.D. from the Jurisprudence and Social Policy program in UC Berkley. Carmel Shachar, J.D., M.P.H.,
is the Executive Director of the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard University, 
Cambridge, MA, USA. She holds a J.D. from Harvard Law School and a Masters of Public Health from the T.H. Chan Harvard 
School of Public Health.
Keywords: Antibody Testing, COVID-19, 
Employment, Ethics, Law, FDA, ADA
Abstract: Employers and governments are inter-
ested in the use of serological (antibody) testing 
to allow people to return to work before there is 
a vaccine for SARS-CoV-2. We articulate the pre-
conditions needed for the implementation of anti-
body testing, including the role of the U.S. Food & 
Drug Administration.
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ments have the authority to mandate testing pro-
grams and whether employers can implement testing 
programs without violating current employment and 
anti-discrimination laws. 
Assumptions
Our analysis rests on a series of assumptions (see Fig-
ure 1). First, we assume that as our understanding of 
SARS-CoV-2 continues to evolve, there will be reli-
able evidence to suggest that the presence of antibod-
ies confers meaningful immunity. This could take the 
form of scientific evidence acceptable to public health 
expert bodies supporting a link between antibod-
ies and long-lasting. Without that, antibody testing 
would not provide useful information about who is at 
risk for COVID-19. 
Second, we assume that there is an antibody test for 
COVID-19 on the market that is accurate and reliable 
with high specificity and sensitivity. We acknowledge 
the fact that no tests will be 100% accurate and reli-
able and that there will always be false positive and 
negative results. An analogy can be perhaps drawn 
from vaccines that are also not perfect but are still 
being (sometimes even mandatorily) used for immu-
nity.5 To be considered ethical, antibody testing pro-
grams must use only FDA authorized tests meeting 
a reasonable threshold of accuracy and reliability. A 
positive antibody test might also need to be coupled 
with a negative PCR test to ensure that an individual 
cannot spread the virus.6 Lastly, our analysis presup-
poses pandemic circumstances, including a high risk 
of infection by leaving self-isolation and a significant 
risk of death for COVID-19 patients. Should a vaccine 
or successful treatments for COVID-19 become avail-
able, or if rates of infection fall dramatically, antibody 
testing as a prerequisite for employment may no lon-
ger be justified.
Regulation of Antibody Tests and Current 
Concerns
It is clear that the majority of our assumptions are 
not yet met. There are serious concerns regarding the 
accuracy of these tests.7 High rates of false positives 
make reliance on these tests unethical because they 
might encourage people who test positive but actu-
ally do not have immunity to take undue risks. It is the 
responsibility of the FDA to ensure that antibody tests 
are ready for widespread clinical use. Recognizing the 
need for speedy action in the face of a pandemic, the 
FDA created two pathways to market that would be 
available only during the public health emergency: 
1) “Emergency Use Authorizations” (EUAs), and 2) a 
May “Policy for Coronavirus Disease-2019 Tests Dur-
ing the Public Health Emergency (Revised)” (May 
Policy).8
The first group of antibody tests for COVID-19 
are available through EUAs. The criteria for issuing 
EUAs are lower than usual (i.e., pre-pandemic) and 
require, for example, only a “reasonable” belief that 
the test “may be effective in diagnosing, treating, or 
preventing” COVID-19.9 After determining that there 
was a public health emergency, the HHS Secretary has 
issued several EUA Declarations, including one for “in 
vitro diagnostics for detection and/or diagnosis of the 
novel coronavirus.”10 Based on this HHS Secretary’s 
Declaration, the FDA may issue EUAs under Section 
564 of the Federal Food, Drug, and Cosmetic Act. To 
date, the FDA has issued several EUAs for SARS-
CoV-2 serological tests.11 
The tests that are available through EUAs have 
already been rushed through evaluation to market. 
Even more concerning is that several available anti-
body tests have not been reviewed by the FDA at all. 
These are tests that belong to the second group men-
tioned above — i.e., have not obtained an EUA, but fall 
within the scope of the FDA’s May Policy. To protect 
the public from a concerning number of antibody tests 
that are performing poorly or are being promoted 
Some of the most significant implementation concerns of an antibody testing 
program as a precondition for employment include concerns about access to 
the workforce, avoiding incentivizing infections, respecting individual privacy 
rights, and addressing questions of equity. While we focus on employment 
specifically, some of these and other ethical concerns have been raised in the 
context of immunity certification efforts that would relate to broader forms of 
freedom of movement such as travel, education, or worship.
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inappropriately, the FDA revised its previous March 
Policy to require commercial manufacturers of anti-
body tests for COVID-19 to submit an EUA request 
within 10 business days.12 Laboratories that are cer-
tified under the Clinical Laboratory Improvement 
Amendments (CLIA) to perform high-complexity 
testing can continue to develop and use antibody tests 
without being required to submit an EUA as long as 
the test has been validated, the FDA has been notified, 
and information has been included in the test reports 
in accordance with the May Policy.13
In particular, at the beginning of the COVID-
19 pandemic, many available COVID-19 tests were 
flawed based on an assessment by the NIH, and some 
health care providers had even used antibody tests 
(wrongly) to diagnose or exclude SARS-CoV-2 infec-
tion, which prompted the FDA to revise its Policy.14 
In light of sound scientific principles, the FDA has 
repeatedly highlighted that health care providers need 
to be aware of the fact that the meaning of these tests 
is limited and that their results cannot be used as the 
only basis to definitely diagnose COVID-19 or exclude 
infection with the virus without creating risks to the 
community and patients.15 Looking into the future and 
broad antibody testing tied to employment, we hope 
that the FDA will learn from its previous mistakes and 
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Ethical Issues
Some of the most significant implementation con-
cerns of an antibody testing program as a precondition 
for employment include concerns about access to the 
workforce, avoiding incentivizing infections, respect-
ing individual privacy rights, and addressing ques-
tions of equity. While we focus on employment spe-
cifically, some of these and other ethical concerns have 
been raised in the context of immunity certification 
efforts that would relate to broader forms of freedom 
of movement such as travel, education, or worship.16 
Access to the Workforce
Overall, antibody testing as a precondition for employ-
ment is most ethical in situations in which the employee 
is uniquely vulnerable or likely to transmit the virus 
to co-workers or clients. Immunization requirements 
can provide insights related to tying access to work 
to COVID-19 immunity. We are comfortable with 
requiring vaccines for certain types of employment. 
For example, several states require certain vaccines 
for health care workers, and some of them have lost 
their jobs for not complying with vaccination require-
ments.17 There is a general consensus that mandatory 
vaccinations for health care workers is ethically justifi-
able because these employees owe their patients duties 
of beneficence and nonmaleficence.18 Health care 
workers are involved with direct patient care, strength-
ening the argument that hospital and clinic employers 
have a special interest in ensuring that their employees 
cannot infect patients/clients. In other words, we want 
these employees to “do no harm” and find it justifiable 
to have their employer require influenza vaccinations 
or proof of immunity against hepatitis B and rubella. 
In 2015, California passed a bill requiring teachers 
and volunteers working in day care facilities to be 
vaccinated against several diseases.19 These immuni-
zation requirements for specific industries can be dis-
tinguished from a broad requirement to demonstrate 
COVID-19 immunity as a precondition of returning to 
any work. 
Nevertheless, if we find it ethically permissible 
to compel certain workers to vaccinate, we should 
similarly find it permissible to impose antibody test-
ing on select industries. Of course, health care work-
ers are in some respects the “easiest” ethical case 
because of their heightened duties to patients, many 
of whom will be particularly vulnerable to COVID-19 
and because they enter a profession which is already 
highly regulated in favor of others. Other industries 
in which there is a heightened risk either to employ-
ees, the public, or to clients/patients may also have 
heightened ethical justifications for antibody testing. 
For example, since grocery store work requires a sig-
nificant level of customer interaction, grocery work-
ers have both increased exposure to SARS-CoV-2 and 
increased opportunities to transmit the virus. Other 
industries that may fall into this heightened category 
are meatpacking, restaurants, and childcare provid-
ers. As service providers, these workers owe a greater 
duty to their customers than citizens sharing a public 
space might owe one another. Restaurants and day-
cares, like health facilities, are heavily regulated, as 
well. These workers are lower paid and more vulnera-
ble than doctors, but they will not necessarily be more 
vulnerable than service workers in healthcare facili-
ties, and further, their very vulnerability may make it 
more important to provide a work environment where 
the risks of COVID-19 are reduced. Because of the 
compelling interest to keep these workplaces free of 
COVID-19 outbreaks, it is ethically justified for either 
states or private employers to require antibody testing 
for those industries.
What about employers in industries that do not 
have heightened justifications for requiring antibody 
testing? It is reasonable for employers to want to avoid 
COVID-19 outbreaks in their businesses. While finan-
cial considerations should not outweigh ethical con-
cerns, ensuring financial sustainability is important, 
especially considering the economic challenges result-
ing from expansive stay-at-home orders. It also ben-
efits employees to have employers who are financially 
stable. Therefore, employees outside of the heightened 
risk category should be allowed to require antibody 
testing if they desire so long as they ethically imple-
ment these programs. Governmental requirements for 
antibody testing in these industries may be ethical but 
the case for these requirements is less compelling than 
in industries with heightened risk factors. Therefore, 
federal and state policymakers should proceed care-
fully with any broader testing requirements. 
Not every antibody testing scheme under this 
rubric is ethical, and implementation has to be ethi-
cal, too. We next explore some concerns that must be 
addressed to ensure that these programs respect indi-
vidual rights and public policy considerations. State 
and federal governments should work with employ-
ers initiating testing programs to ensure the ethical 
implementation of these programs.
Incentivizing Infection
A system that ties immunity to the ability to work 
creates a perverse incentive. If the reward for immu-
nity is the ticket to employment, people who have not 
been exposed to the virus may attempt to contract it 
in the hope of developing antibodies. We may see a 
proliferation of “COVID-19 parties”20 like the “chick-
enpox parties” that some parents facilitated before a 
Gerke et al.
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vaccine was available. In this respect, antibody test-
ing is significantly different from vaccine mandates. 
If an employee is missing a mandated vaccination (for 
example, a flu shot for a health care worker) then they 
can come into compliance with the mandate by obtain-
ing the needed immunization. On the other hand, if an 
employee cannot demonstrate COVID-19 antibodies, 
the only active step they could take to change the situ-
ation would be to purposefully expose themselves to 
COVID-19. In the first case, the employee can meet 
requirements and obtain employment by taking a safe 
step that promotes public health. In the other case, 
the only active option available to the employee is 
unsafe and undermines public health. In the case of 
health care workers, purposefully seeking out infec-
tion would mean that health care workers must miss 
work as they recover. In an already stretched health 
care system, creating an incentive for health care 
workers to be absent from their clinical responsibilties 
may harm patients. 
Rewarding immunity also potentially undermines 
the public health efforts of mitigating the spread of 
COVID-19. Conditioning work on immunity — by 
incentivizing getting infected — may result in a surge 
in infections that hospitals may not be able to handle. 
Moreover, this may erode trust in the public health 
system. People who have followed public health guid-
ance and avoided developing COVID-19 may now feel 
penalized by the system by not being able to return to 
work. 
Any antibody testing requirements implemented 
must be accompanied by policy solutions to address 
the incentives problem as well. This is true even 
if the antibody testing program would be entirely 
employer initiated, because we do not want these 
programs to undermine public health goals. The first 
choice should always be to make reasonable accom-
modations rather than bar individuals from work. In 
some cases, it is ethically justifiable for the employer 
to require employees to pass the test. The hospitality 
and childcare industries, in particular, may find it dif-
ficult to redeploy workers because of a limited number 
of remote or non-client facing positions. But to avoid 
creating a perverse incentive, most employers should 
avoid restricting employment to only those COVID-19 
immune unless it is impossible to mitigate risk. Other 
solutions include using antibody testing to create con-
tingency plans for if an outbreak occurs in their local-
ity, in which case immune workers can keep coming 
in and non-immune work from home. Governments 
should also invest in retraining programs to ensure 
that no one is entirely barred from employment due 
to their immunity status. Moreover, antibody testing 
programs must be incorporated and harmonized into 
reopening policies. For example, retail stores should 
not be able to circumvent stay-at-home orders by con-
ducting antibody testing. Lastly, antibody testing pro-
grams should always be coupled with comprehensive 
and thoughtful educational programs and counseling 
should be offered for those that are reluctant to take 
such test.21 
Privacy 
Another challenge of a system that relies on antibody 
testing to return to work is that it requires individu-
als to share private medical information with their 
employers, government agencies, and other stakehold-
ers. Embracing a widespread antibody testing regi-
men would require us to rethink our privacy expecta-
tions, balancing individuals’ interests in controlling 
their health information with public health interests 
in sharing the same data.
Pre-pandemic, there was an expectation that 
employers would generally not be privy to their 
employees’ medical information. For example, the 
Health Insurance Portability and Accountability 
Act requires that “hybrid entities,” an employer who 
offers a self-insured health plan to its employees, erect 
a “firewall” between the part of the company that 
administers the plan and the rest of the company.22 
The requirement to establish a firewall suggests that 
we are uncomfortable with employers having broad 
access to their employees’ medical information. 
On the other hand, it is widely acknowledged that 
a certain amount of disclosure is necessary for cer-
tain workplaces. For example, pilots and truck drivers 
are routinely tested for drugs and alcohol use.23 Most 
health care employers ask for immunization histories 
from their employees. Some states even require health 
care employers to ensure that their employees have 
certain vaccinations.24 This suggests that our discom-
fort with employers’ demanding medical information 
can be mitigated by sufficient justification. For exam-
ple, pilots or truck drivers operating under the influ-
ence can cause crashes. Our discomfort with allowing 
employers to demand health information without 
sufficient cause suggests that a narrower immunity 
requirement would be less fraught from a privacy per-
spective. Further, in the context of the COVID-19 pan-
demic, our expectations of medical privacy may already 
be changing. As part of reopening, many businesses 
conduct temperature checks for employees, so are 
already registering and keeping medical information. 
Arguably, a less frequent antibody test may reduce the 
collection of medical information, compared to daily 
temperature checks or symptom monitoring.
To respect individual privacy, we should be sure to 
limit antibody testing results to as few parties as pos-
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sible. Employers would need to keep individual anti-
body testing information confidential and should not 
be permitted to disclose it to patients or clients. To 
avoid violating their employees’ privacy, employers 
would be able to disclose their plans for ensuring a safe 
environment for their clients (such as noting that all 
employees must take their temperature before report-
ing for work) but not to guarantee or disclose specific 
health status for individual employees. These privacy 
measures should be developed anyway, to respond to 
other health monitoring efforts, and can be applied to 
antibody testing too.
Equity
This pandemic has already affected people in inequita-
ble ways. Data from 2017-2018 show that while about 
half of those in management, business, and financial 
activity positions could work from home, only 8.8% 
of those in leisure and hospitality jobs could do so.25 
It is not surprising that the unemployment rate for 
the leisure and hospitality sector was about seven 
times higher than that of the finance sector in April 
2020.26 Not only are hospitality and leisure work-
ers likely to find themselves unemployed, but with 
a pre-pandemic average hourly wage of about $16/
hour, they may not have the savings to withstand pro-
longed unemployment.27 In general, low wage work-
ers are three times less likely to have work that can be 
done remotely and they are also more likely to have 
less education, to be young, to belong to an ethnic 
minority group or to be immigrants, than those who 
can work remotely,28 making it very difficult for these 
people to secure any employment under stay-at-home 
orders. Hall and Studdert suggest that an immunity-
based employment system may actually benefit some 
individuals with lower socioeconomic status (SES) 
since these populations may have a higher prevalence 
of antibodies due to exposure.29 Nevertheless, since 
the vast majority of Americans at all socio-economic 
levels have not contracted COVID-19, we anticipate 
that preconditioning a return to work on antibody 
testing would not benefit the majority of those with 
lower SES.
In order to address equity concerns, antibody test-
ing must be widely available so that no one seek-
ing employment is prevented from obtaining a test. 
Depending on the test(s), large-scale testing may 
require significant resources such as trained person-
nel, labs, and personal protective equipment. If these 
tests are not widely accessible, especially for those who 
may need them the most to return to work, inequities 
will only widen. An ethical testing program requires 
that the employer cover the cost of the tests, just as 
employers are required to cover protective equipment 
where it is needed. This raises its own problems of 
access, particularly for small businesses. It will also 
be important to ensure that those who test negative 
for the antibody test are not disadvantaged. Federal, 
state, and business leaders should build programs to 
directly address the inequitable impact that testing 
could have on the ability of those with lower SES to 
return to work. 
Another equity concern, which merits its own paper, 
will be the impact of antibody testing on vaccine allo-
cation. Many employers already offer flu vaccinations 
to their employees, and it is possible that they will offer 
similar access to the COVID-19 vaccination when it is 
developed and approved. Potentially, this will coincide 
with an improved understanding of COVID-19 anti-
bodies. If antibodies offer some protection, but not 
as complete protection as the vaccine, should we take 
into account antibody status when providing access 
to the COVID-19 vaccine? Would principles of equity 
argue that we should actually prioritize those who 
have already suffered through one bout of COVID-
19? If we decide that people with antibodies should 
be deprioritized for vaccine access, because they have 
at least partial protection, how should this be harmo-
nized with the ability to work? 
Legal and Policy Issues
Beyond ethical concerns, including those flagged 
above, antibody requirements for access to work raise 
significant legal questions. Distinct questions are 
raised by government required and employer initiated 
testing. For government required antibody testing, 
the operative question is whether there is a constitu-
tional barrier to testing. By contrast, testing initiatives 
imposed by private employers raise a different set of 
legal concerns. Foremost is whether employers are 
allowed to require antibody testing as a precondition 
to work or whether these demands would run afoul of 
employment and anti-discrimination laws (or collec-
tive bargaining agreements — but because those are 
very agreement specific, we do not delve deeply into 
them).
Government Mandated Antibody Testing Programs
The requirement to “pass an antibody test” as a pre-
condition for returning to work may come from fed-
eral or state policymakers. The federal government 
may lack the power to impose a nationally required 
antibody testing regimen since its powers are limited 
to constitutionally allocated powers. Under the com-
merce clause of the United States Constitution, which 
gives Congress the power to regulate interstate and 
international commerce, the federal government can 
require antibody testing where a business is engaged 
Gerke et al.
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in interstate commerce — including transportation of 
people or goods across state lines (or internationally), 
and that would cover a sizable portion of the work-
force. Trying to require it from purely intrastate busi-
nesses, however, could run into trouble, unless there 
are good grounds to see them as having substantial 
effect on interstate commerce.
States, on the other hand, have broad police pow-
ers that would allow them to implement required 
antibody testing programs. As mentioned above, 
some states have required immunization mandates 
for influenza for health care workers. Those powers 
have also been used to impose stay-at-home orders 
in the vast majority of states. Requiring antibody cer-
tificates before returning to work is less coercive than 
shelter-at-home, and when imposed generally, and 
with appropriate exemptions, may not violate federal 
non-discrimination acts. The equal protection clause 
would also not be a barrier: Since not being immune 
against COVID-19 does not fall into a protected cate-
gory, the applicable standard of review would be ratio-
nal basis, and it is rational to treat people immune to 
COVID-19 different than those who are not — the lat-
ter are at higher risk of getting and transmitting the 
disease, posing a risk to others. 
Private, Employer-Based Antibody Testing Programs
Right now, few would consider not having COVID-
19 immunity as a disability. Tying access to social 
goods like employment to COVID-19 immunity raises 
an interesting possibility that not having COVID-19 
immunity would become, in some ways, a socially con-
structed disability. This would be somewhat analogous 
to the argument that disability should be understood 
as “mere difference” — i.e., that non-normative health 
status or biology becomes problematic because of 
social structures and expectations rather than because 
of an intrinsically negative quality.30 The Americans 
with Disabilities Act (ADA) defines disability as “(A) a 
physical or mental impairment that substantially lim-
its one or more major life activities of such individual; 
(B) a record of such impairment; or (C) [could be] 
regarded as having such an impairment.”31 
In Bragdon v. Abbott, the Supreme Court held that 
asymptomatic people with HIV qualified as disabled 
for the purposes of the ADA.32 The Supreme Court 
focused on the immediate physiological effects of 
even an asymptomatic HIV infection, noting that the 
“assault on the immune system is immediate.”33 The 
Court then found that even an asymptomatic HIV 
infection limited the major life activity of reproduc-
tion.34 The Court’s emphasis on the physiological 
impact of HIV would suggest that Bragdon is not 
actually precedent for declaring a lack of COVID-19 
immunity to be a disability under the ADA. In fact, the 
Court even argued that asymptomatic HIV is a “mis-
nomer” because of the clinical impacts that “persist 
throughout.”35 Obviously, a lack of COVID-19 immu-
nity is the opposite of an “immediate assault on the 
immune system” because it means that an individual 
has not been exposed to the virus. 
A stronger argument is that not having COVID-
19 immunity could qualify as a disability under the 
“regarded as” prong of the ADA. This prong requires 
an individual to demonstrate that they are perceived 
as being disabled, regardless of whether they have 
an actual physical or mental impairment. In Cook v. 
Rhode Island Department of Mental Health, Retarda-
tion, and Hospitals, the First Circuit concluded that a 
morbidly obese woman was “regarded as” disabled by 
her employer because of its concerns around limited 
mobility and heightened risk of heart disease.36 The 
First Circuit interpreted the “regarded as” prong to 
allow a suit to be “brought against a warehouse opera-
tor who refuses to hire all turquoise-eyed applicants 
solely because he believes that people with such color-
ing are universally incapable of lifting large crates.”37 
The EEOC, in its explanation of the “regarded as” 
prong, cited to “Congress’s understanding that 
‘unfounded concerns, mistaken beliefs, fears, myths, 
or prejudice about disabilities are often just as dis-
abling as actual impairments,’ and [its] correspond-
ing desire to prohibit discrimination founded on such 
perceptions.”38
A lack of COVID-19 immunity could potentially fall 
under the “regarded as” prong if employers refuse to 
hire people who lack COVID-19 immunity because of 
the perception that they will get sick and not be able 
to perform their job duties. This could potentially 
limit the ability of employers to require or use anti-
body testing to determine who may work. However, 
we should note that this is a potentially problematic 
claim: Without testing, there would be no perception 
of lack of immunity, and using the lack of immunity 
discovered in testing as a disability would not be an 
argument against testing. It might be an argument 
against treating people who tested negative differ-
ently, but employers could potentially make a claim 
that the unprotected are a direct threat to others — 
an exception under the ADA. Further, seeing lack of 
immunity as a disability could limit employers’ ability 
to demand, for example, vaccines — an undesirable 
policy consequence. 
Current guidance from the EEOC allows employ-
ers to require a COVID-19 test, before returning to 
work because in the circumstances, an individual with 
the virus would be a direct threat to others.39 By con-
trast, in a technical assistance questions and answers 
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document, the EEOC concludes that “an antibody 
test at this time does not meet the ADA’s ‘job related 
and consistent with business necessity’ standard for 
medical examinations or inquiries for current employ-
ees.”40 This determination was based on the Centers 
for Disease Control and Prevention’s (CDC) Interim 
Guidelines for COVID-10 Antibody Testing, which 
concluded that antibody test results “should not be 
used to make decisions about returning persons to 
the workplace.”41 The CDC’s recommendations, in 
turn, were based upon the limited understanding of 
any potential immunity or other benefit conferred by 
COVID-19 antibodies. Therefore, it is possible that in 
the future, when the science regarding antibody test-
ing improves, that the CDC will change its recommen-
dations and perhaps trigger the EEOC to reevaluate 
antibody testing, as it permits COVID-19 testing. 
The ADA permits employers to require medical 
examinations of entering employees, provided all enter-
ing employees in the same job category are required 
to undergo the medical examination. Therefore, once 
antibody testing provides more useful and actionable 
information and the CDC changes its Interim Guide-
lines, employers would likely be able to require anti-
body testing of all incoming employees. It is less clear 
if employers could rescind offers of employment based 
on the result of these tests. In terms of testing cur-
rent employees for antibodies, the key inquiry will be 
whether these individuals either 1) post a direct threat 
to the workplace or they would be unable to perform 
their essential job functions. Admittedly, it is more of a 
stretch to argue that people without COVID-19 immu-
nity would be a direct threat to their workplaces, in 
contrast to the clear, direct threat posed by those with 
an active COVID-19 infection. But for workplaces that 
deal with especially vulnerable clients, such as nurs-
ing homes or hospitals, it may be possible to make the 
argument that anyone vulnerable to infection presents 
a significant risk. Furthermore, workplaces in which it 
is likely that employees will be exposed to COVID-19, 
such as grocery strores, could argue that an employee’s 
ability to perform their essential job functions will be 
impaired by their vulnerability to infection. Therefore, 
it is likely that, once we better understand what, if any, 
immunity is conferred by COVID-19 antibodies, at 
least some employers will be able to require antibody 
testing of current employees as “job-related and con-
sistent with business necessity.” 
Besides the ADA, we can expect some people to 
raise religious objections to antibody testing, as we see 
in the influenza vaccines mandate context. The claim 
would be that the employee has religious objections to 
the testing and that under the Civil Rights Act of 1964, 
employers owe them reasonable accommodations.42 
The range of plausible religious claims is very limited, 
and sincerity can be an issue. Claims that are raised 
against vaccines, such as inserting animal products or 
other things into the body, will not be applicable. Fur-
ther, the available accommodations are very limited — 
i.e., working at home (or in isolation), where feasible, 
which would be more viable for some jobs than oth-
ers. Mask and glove requirements may be a reasonable 
accommodation, but those carry costs. Remote work 
would be available for some workplaces, but not others. 
Preconditioning access to employment on antibody testing programs 
has significant parallels to existing immunization requirements in select 
industries. Because we already allow industries with a heightened justification 
to compel their employees to vaccinate, we believe that antibody testing 
programs are likewise ethically permissible for these industries.  
Similarly, we have not identified a major legal impediment to these programs. 
In industries without a heightened risk, we believe that employer initiated 
testing programs would be ethically permissible. State requirements 
for testing in lower-risk industries, which is likely ethically and legally 
permissible, is less compelling than for higher risk industries.  
Any antibody testing program, however, must be carefully implemented  
to address other ethical concerns, such as privacy and equity.
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Employers likely have a good argument that exempt-
ing employees from antibody testing requirements is 
an undue burden (which, under the Civil Rights Act of 
1964, means anything more than a de minimis cost).43 
Conclusions
Preconditioning access to employment on antibody 
testing programs has significant parallels to exist-
ing immunization requirements in select industries. 
Because we already allow industries with a heightened 
justification to compel their employees to vaccinate, 
we believe that antibody testing programs are likewise 
ethically permissible for these industries. Similarly, we 
have not identified a major legal impediment to these 
programs. In industries without a heightened risk, we 
believe that employer initiated testing programs would 
be ethically permissible. State requirements for test-
ing in lower-risk industries, which is likely ethically 
and legally permissible, is less compelling than for 
higher risk industries. Any antibody testing program, 
however, must be carefully implemented to address 
other ethical concerns, such as privacy and equity. A 
summary of our conclusions is shown in Figure 1.
Note
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